Cargando…
Non-conventional therapeutics for oral infections
As our knowledge of host-microbial interactions within the oral cavity increases, future treatments are likely to be more targeted. For example, efforts to target a single species or key virulence factors that they produce, while maintaining the natural balance of the resident oral microbiota that a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601402/ https://www.ncbi.nlm.nih.gov/pubmed/25668296 http://dx.doi.org/10.4161/21505594.2014.983783 |
_version_ | 1782394543525593088 |
---|---|
author | Allaker, Robert P Ian Douglas, CW |
author_facet | Allaker, Robert P Ian Douglas, CW |
author_sort | Allaker, Robert P |
collection | PubMed |
description | As our knowledge of host-microbial interactions within the oral cavity increases, future treatments are likely to be more targeted. For example, efforts to target a single species or key virulence factors that they produce, while maintaining the natural balance of the resident oral microbiota that acts to modulate the host immune response would be an advantage. Targeted approaches may be directed at the black-pigmented anaerobes, Porphyromonas gingivalis and Prevotella intermedia, associated with periodontitis. Such pigments provide an opportunity for targeted phototherapy with high-intensity monochromatic light. Functional inhibition approaches, including the use of enzyme inhibitors, are also being explored to control periodontitis. More general disruption of dental plaque through the use of enzymes and detergents, alone and in combination, shows much promise. The use of probiotics and prebiotics to improve gastrointestinal health has now led to an interest in using these approaches to control oral disease. More recently the potential of antimicrobial peptides and nanotechnology, through the application of nanoparticles with biocidal, anti-adhesive and delivery capabilities, has been explored. The aim of this review is to consider the current status as regards non-conventional treatment approaches for oral infections with particular emphasis on the plaque-related diseases. |
format | Online Article Text |
id | pubmed-4601402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-46014022016-02-03 Non-conventional therapeutics for oral infections Allaker, Robert P Ian Douglas, CW Virulence Review - Commissioned As our knowledge of host-microbial interactions within the oral cavity increases, future treatments are likely to be more targeted. For example, efforts to target a single species or key virulence factors that they produce, while maintaining the natural balance of the resident oral microbiota that acts to modulate the host immune response would be an advantage. Targeted approaches may be directed at the black-pigmented anaerobes, Porphyromonas gingivalis and Prevotella intermedia, associated with periodontitis. Such pigments provide an opportunity for targeted phototherapy with high-intensity monochromatic light. Functional inhibition approaches, including the use of enzyme inhibitors, are also being explored to control periodontitis. More general disruption of dental plaque through the use of enzymes and detergents, alone and in combination, shows much promise. The use of probiotics and prebiotics to improve gastrointestinal health has now led to an interest in using these approaches to control oral disease. More recently the potential of antimicrobial peptides and nanotechnology, through the application of nanoparticles with biocidal, anti-adhesive and delivery capabilities, has been explored. The aim of this review is to consider the current status as regards non-conventional treatment approaches for oral infections with particular emphasis on the plaque-related diseases. Taylor & Francis 2015-02-10 /pmc/articles/PMC4601402/ /pubmed/25668296 http://dx.doi.org/10.4161/21505594.2014.983783 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Review - Commissioned Allaker, Robert P Ian Douglas, CW Non-conventional therapeutics for oral infections |
title | Non-conventional therapeutics for oral infections |
title_full | Non-conventional therapeutics for oral infections |
title_fullStr | Non-conventional therapeutics for oral infections |
title_full_unstemmed | Non-conventional therapeutics for oral infections |
title_short | Non-conventional therapeutics for oral infections |
title_sort | non-conventional therapeutics for oral infections |
topic | Review - Commissioned |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601402/ https://www.ncbi.nlm.nih.gov/pubmed/25668296 http://dx.doi.org/10.4161/21505594.2014.983783 |
work_keys_str_mv | AT allakerrobertp nonconventionaltherapeuticsfororalinfections AT iandouglascw nonconventionaltherapeuticsfororalinfections |